Intellia Loses 21.6% in a Week: How Should You Play the Stock?

Intellia Therapeutics, Inc. (NTLA) lost 21.6% in a week as investors were disappointed with the company’s plans for portfolio reorganization.Intellia is a clinical-stage gene editing company focused on developing innovative CRISPR-based therapies. As part of the recently announced portfolio reorganization, NTLA is planning to prioritize the development of its late-stage programs — NTLA-2002 and nexiguran ziclumeran (nex-z). The company will also reduce its workforce by 27% in 2025.NTLA Underperforms Industr ...